A thesis backed by fundamentals.
Lilac Insights pairs scientific leadership with disciplined operations: positive EBITDA, year-on-year growth, and the largest KOL network in Indian clinical genomics. We are building the category leader — and we are doing it profitably.
Positive EBITDA
A genomics business with healthy, proven unit economics.
Y-o-Y growth
Consistent year-on-year growth across services and geographies.
Largest KOL network
Anchored by globally respected key opinion leaders.
National reach
400+ cities, 4,500+ hospitals and clinics served.
Clinical genomics in India is compounding.
Screening is moving from optional to standard of care, oncology is going molecular, and newborn screening is spreading beyond metro hospitals. Lilac Insights already owns the protocols, the laboratory footprint and the clinician relationships that this shift runs on.
- India's first evidence-based prenatal screening program, on FMF UK protocols since 2011
- India's first combined FISH + Sequencing + IHC cancer genetics service
- India's only private diagnosis-to-management metabolic genetics program
- Seven laboratory locations and a collection network across the country
Get the investor deck.
Tell us who you are and our team will share the investor deck and follow up personally.
Thank you — your request is on its way.
Our team will share the investor deck with you shortly.